

At the pulse of heart diseases

Cardior Pharmaceuticals is a leading clinical-stage biopharmaceutical company pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart. Cardior's therapeutic approach uses distinctive non-coding RNAs as an innovative platform for addressing the root causes of cardiac dysfunction. The company aspires to bring transformative therapeutics and diagnostics to patients and thereby make a lasting impact on the treatment of cardiac diseases worldwide.

Key facts



Founded 2016 and located in Hanover, Germany



Addressing cardiac diseases with ncRNAs



Broad proprietary platform



Series A: € 15M
Series B: € 64M




Lead candidate with blockbuster potential




Experienced management team


Technology



Diseased cardiac tissue



Cardior's treatment



Cardiac tissue normalization

Cardior's strong foundation for growth and innovation is based on non-coding RNAs (ncRNAs) that orchestrate fundamental cellular cardiac processes.

Targeting ncRNAs by Cardior's innovative therapeutics serve as a disease curating approach by triggering a concerted therapeutic effect against key hallmarks of heart disease, including cardiac remodeling processes such as pathological hypertrophy, impaired contractility and fibrosis.

From the company's growing pipeline of product compounds, the lead candidate demonstrates safety, tolerability, strong target engagement, initial efficacy and is currently being evaluated in a Phase 2 clinical trial in heart failure patients (NCT05350969).



Signaling pathways



RNA




RNA bound by Cardior's oligonucleotide

Key Publications



Pipeline



Our lead candidate CDR132L is an inhibitor directed against miRNA132, designed to halt and reverse the development of detrimental cardiac remodeling. As a therapeutic candidate, CDR132L has several distinguishing features:

- **CDR132L** selectively blocks aberrant miRNA132 levels contributing to improved cardiac systolic and diastolic function in patients
- **CDR132L** has the potential to prolong the patient's life span as well as improve quality of life
- **CDR132L** is a highly stable watersoluble oligonucleotide formulated for parenteral or subcutaneous application

The advantages of the Cardior platform

- ✓ Based on world-leading expertise in the therapeutic modulation of RNAs through synthetic oligonucleotides
- ✓ Highly stable and effective RNA therapies resulting from a proprietary discovery engine
- ✓ Pre-clinical proof-of-concept demonstrating the potential of the approach and first clinical evaluation completed
- ✓ Deep understanding of the complex interplay of multiple disease-causing mechanisms and the role of ncRNAs
- ✓ Effective target modulation and targeted delivery into the heart achieved
- ✓ Successful scale up of a fast and cost-efficient GMP grade manufacturing

Management Team

Claudia Ulbrich, MD
CEO & Co-Founder

Prof. Thomas Thum, MD
CSO & Founder

Rahul Agrawal, MD
CMO

Board

Claus Andersson
PhD

Simone Botti
PhD

Christoph Broja

Martin Crook
PhD

Luc Debruyne

Ulrich Granzer
PhD

Russell Greig
PhD, Chairman

Markus Hosang
PhD, Vice-chairman

Scientific Advisory Board

Prof. Johann Bauersachs
MD

Prof. Javed Butler
MD

Prof. Perry Elliott
MD

Gerasimos Filippatos
MD, PhD

Arthur A. Levin
PhD

Prof. Douglas L. Mann
MD

Prof. Scott Solomon
MD

Barry Ticho
MD, PhD

Prof. Faiez Zannad
MD, PhD

Investors

BioMed  **Partners**

 **Bristol Myers Squibb**

COPARION



inkef capital



Cardior Pharmaceuticals GmbH
Hollerithallee 20
30419 Hannover

Email
info@cardior.de

Phone
+49 511 3385 9930

Find us on social media

